Omalizumab use during pregnancy for CIU: a tertiary care experience.

Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C

Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C.

Affiliation

Cuervo-Pardo L; Medicine Institute, Cleveland Clinic, OH, USA.
Barcena-Blanch M; Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, OH, USA.
Radojicic C; Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic. 9500 Euclid Ave, A90, Cleveland, OH 44195, USA Phone: +1 216 986 4000 Fax: +1 216 445 2104 E-mail: radojic@ccf.org.

Eur Ann Allergy Clin Immunol ; 48(4): 145-6, 2016 Jul.

Article in En | MEDLINE | ID: mdl-27425170

Subject(s)

Anti-Allergic Agents/therapeutic use; Immunosuppressive Agents/therapeutic use; Omalizumab/therapeutic use; Pregnancy Complications/drug therapy; Tertiary Care Centers; Urticaria/drug therapy; Adult; Anti-Allergic Agents/adverse effects; Chronic Disease; Female; Humans; Immunosuppressive Agents/adverse effects; Ohio; Omalizumab/adverse effects; Pregnancy; Pregnancy Complications/diagnosis; Remission Induction; Risk Assessment; Treatment Outcome; Urticaria/diagnosis

Key words

Omalizumab; pregnancy; urticaria

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pregnancy Complications / Urticaria / Anti-Allergic Agents / Tertiary Care Centers / Omalizumab / Immunosuppressive Agents Type of study: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limits: Adult / Female / Humans / Pregnancy Country/Region as subject: America do norte Language: En Journal: Eur Ann Allergy Clin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2016 Document type: Article Affiliation country: United States Country of publication: Italy

Search on Google

Add to My VHL

XML

PubMed Links